Metagenomics of the gut microbiome of individuals treated with rifaximin
The GALA-RIF trial, an investigator-initiated, randomized, double-blind, placebo-controlled, single-center, phase 2 study, was conducted to evaluate the efficacy of rifaximin-a in patients diagnosed with alcohol-related liver disease through liver biopsy